MARKET

NVCN

NVCN

Neovasc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8220
-0.0011
-0.13%
After Hours: 0.8200 -0.002 -0.24% 18:06 11/25 EST
OPEN
0.8400
PREV CLOSE
0.8231
HIGH
0.8500
LOW
0.8106
VOLUME
312.43K
TURNOVER
--
52 WEEK HIGH
8.65
52 WEEK LOW
0.7100
MARKET CAP
18.62M
P/E (TTM)
-0.2482
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Neovasc to Participate in Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. Fred Colen, Neovasc's President and Chief Executive Officer, will deliver a presentation at 11:00 am EST. Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, ...
Newsfile · 11/16 21:46
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 29)
Benzinga · 10/30 12:09
Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/29 17:35
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
Mid-Afternoon Market Update: Dow Tumbles Over 800 Points; Community Health Systems Shares Gain
Toward the end of trading Wednesday, the Dow traded down 3.02% to 26,632.47 while the NASDAQ fell 3.08% to 11,078.05. The S&P also fell, dropping 2.99% to 3,289.29.
Benzinga · 10/28 18:40
Neovasc Reports FDA Circulatory System Devices Advisory Panel Voted Against Effectiveness, Benefits Outweighing Risks For Co.'s Neovasc Reducer, Voted In Favor Of Safety
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the United States Food and Drug Administration’s (FDA’s) Circulatory System Devices
Benzinga · 10/28 11:21
Cassava Sciences, Medigus leads healthcare gainers, Neovasc, ProPhase Labs among major losers
Gainers: Cassava Sciences (SAVA) +13%, Medigus (MDGS) +10%, STRATA Skin Sciences (SSKN) +9%, CASI Pharmaceuticals (CASI) +8%, BOQI International Medical (BIMI) +7%.Losers: Neovasc (NVCN) -14%, ProPhase Labs (PRPH) -14%, Milestone Pharmaceuticals (MIST) -13%, Aptose Biosciences (APTO) -9%, Aileron Therapeutics (ALRN) -7%.
Seekingalpha · 10/23 14:58
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVCN. Analyze the recent business situations of Neovasc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVCN stock price target is 4.385 with a high estimate of 5.00 and a low estimate of 3.770.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 3.99M
% Owned: 17.60%
Shares Outstanding: 22.65M
TypeInstitutionsShares
Increased
5
833.84K
New
5
296.70K
Decreased
7
369.96K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.24%
Healthcare Equipment & Supplies
-0.25%
Key Executives
Chairman/Independent Director
Steven Rubin
President/Chief Executive Officer
Fred Colen
Chief Financial Officer/Secretary/IR Contact Officer
Christopher Clark
Chief Operating Officer
Bill Little
Vice President
Vicki Bebeau
Vice President
Aaron Chalekian
Other
John Panton
Director
Alexei Marko
Director
Norman Radow
Independent Director
Paul Geyer
Independent Director
Douglas Janzen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NVCN
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neovasc Inc stock information, including NASDAQ:NVCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCN stock methods without spending real money on the virtual paper trading platform.